Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Regeneus Ltd. ( (AU:CMB) ) just unveiled an announcement.
Cambium Bio Limited has signed a licensing agreement with Keke Medtech, Inc. to develop and commercialize its fibrin biologic for dental applications, marking a significant milestone for the company. This deal not only provides Cambium with non-dilutive funding but also validates its human platelet lysate technology, allowing the company to focus on its primary dry eye disease program while expanding its platform’s potential in complementary areas.
More about Regeneus Ltd.
Cambium Bio Limited is a clinical-stage regenerative medicine company specializing in the development of human platelet lysate-derived biologics. The company focuses on creating therapeutic products for various medical fields, including ophthalmology, orthopedics, wound healing, and dentistry.
Average Trading Volume: 15,357
Technical Sentiment Signal: Sell
Current Market Cap: A$10.74M
For an in-depth examination of CMB stock, go to TipRanks’ Overview page.